Opportunity ID: 358720

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942525ALSRPCOBA
Funding Opportunity Title: DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 6
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Apr 18, 2025
Last Updated Date: May 23, 2025
Original Closing Date for Applications: Aug 27, 2025
Current Closing Date for Applications: Aug 27, 2025
Archive Date: Sep 26, 2025
Estimated Total Program Funding: $6,300,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.

 

To meet the intent of the funding opportunity, applications must address ONE or BOTH of the following focus areas:

  • Clinical Biomarkers: Identification, development, and/or validation of promising biomarkers for ALS. Biomarkers may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers.

  • Clinical Outcomes: Identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include optimization of current outcome measures already in use.

 

Both focus areas are permitted to utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.

 

Distinctive Features: Applications proposing prospective biospecimen collection or participant enrollment are required to incorporate a Community Collaboration, as described in Attachment 9.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Version History

Version Modification Description Updated Date
Pages 4 and 10 of the Program Announcement (PA) have been updated to reflect a change in the funding details from a total direct cost cap to a total cost cap. The Estimated Total Program Funding amount has been updated in the PA and synopsis. Additionally, a weblink under section 6.4 has been updated in the PA (page 27). May 23, 2025
Apr 18, 2025

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942525ALSRPCOBA
Funding Opportunity Title: DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 6
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Apr 18, 2025
Last Updated Date: May 23, 2025
Original Closing Date for Applications: Aug 27, 2025
Current Closing Date for Applications: Aug 27, 2025
Archive Date: Sep 26, 2025
Estimated Total Program Funding: $6,300,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.

 

To meet the intent of the funding opportunity, applications must address ONE or BOTH of the following focus areas:

  • Clinical Biomarkers: Identification, development, and/or validation of promising biomarkers for ALS. Biomarkers may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers.

  • Clinical Outcomes: Identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include optimization of current outcome measures already in use.

 

Both focus areas are permitted to utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.

 

Distinctive Features: Applications proposing prospective biospecimen collection or participant enrollment are required to incorporate a Community Collaboration, as described in Attachment 9.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: HT942525ALSRPCOBA
Funding Opportunity Title: DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Science and Technology and other Research and Development
Category Explanation:
Expected Number of Awards: 5
Assistance Listings: 12.420 — Military Medical Research and Development
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Apr 18, 2025
Last Updated Date: Apr 18, 2025
Original Closing Date for Applications:
Current Closing Date for Applications: Aug 27, 2025
Archive Date: Sep 26, 2025
Estimated Total Program Funding: $6,200,000
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Dept. of the Army — USAMRAA
Description:

Summary: The fiscal year 2025 (FY25) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients.

 

To meet the intent of the funding opportunity, applications must address ONE or BOTH of the following focus areas:

  • Clinical Biomarkers: Identification, development, and/or validation of promising biomarkers for ALS. Biomarkers may include, but are not limited to susceptibility/risk, diagnostic, monitoring/disease progression, prognostic, predictive, response, or safety biomarkers.

  • Clinical Outcomes: Identification, development, and/or validation of clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. Projects may include optimization of current outcome measures already in use.

 

Both focus areas are permitted to utilize digital health measures, including wearable devices, smart-phone sensors, video or voice recordings, imaging studies, or other devices which record disease-relevant physiological data and/or outcomes.

 

Distinctive Features: Applications proposing prospective biospecimen collection or participant enrollment are required to incorporate a Community Collaboration, as described in Attachment 9.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

CDMRP Help Desk

Phone: 301-682-5507

Email: help@eBRAP.org
Email:help@eBRAP.org

Folder 358720 Full Announcement-FY25 ALSRP COBA -> HT9425FY25ALSRPCOBA_updated.pdf

Packages

Agency Contact Information: CDMRP Help Desk
Phone: 301-682-5507
Email: help@eBRAP.org
Email: help@eBRAP.org
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
12.420 PKG00290605 Apr 18, 2025 Aug 27, 2025 View

Package 1

Mandatory forms

358720 RR_SF424_5_0-5.0.pdf

358720 AttachmentForm_1_2-1.2.pdf

358720 RR_PersonalData_1_2-1.2.pdf

358720 RR_KeyPersonExpanded_4_0-4.0.pdf

358720 RR_Budget_3_0-3.0.pdf

358720 PerformanceSite_4_0-4.0.pdf

Optional forms

358720 RR_SubawardBudget30_3_0-3.0.pdf

2025-07-13T19:19:39-05:00

Share This Post, Choose Your Platform!

About the Author: